Hydroxychloroquine & hypoxic pneumonia

Researchers in France examined the medical records of 84 patients with COVID-19 requiring oxygen who received hydroxychloroquine (600 mg daily) and 97 similar patients who did not get the drug. The primary outcome — transfer to the ICU or death from any cause within 7 days — did not differ significantly between the groups (in a weighted analysis, roughly 21%-22% of patients). The researchers say the findings “do not support the use of [hydroxychloroquine] in patients hospitalised for a documented SARS-CoV-2 pneumonia.” The study appears on the preprint server medRxiv.

Hydroxychloroquine study on medRxiv (not peer-reviewed)